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Abstract: In this paper we establish the xenograft leukemia model with stable multidrug 
resistance in nude mice and to investigate the reversal effect of 5-bromotetrandrine (5-BrTet) 
and magnetic nanoparticle of Fe3O4 (MNP-Fe3O4) combined with daunorubicin (DNR) in vivo. 
Two subclones of K562 and K562/A02 cells were inoculated subcutaneously into the back of 
athymic nude mice (1 × 107 cells/each) respectively to establish leukemia xenograft models. 
Drug-resistant and sensitive tumor-bearing nude mice were assigned randomly into ﬁ  ve groups 
which were treated with normal saline; DNR; NP-Fe3O4 combined with DNR; 5-BrTet combined 
with DNR; 5-BrTet and MNP-Fe3O4 combined with DNR, respectively. The incidence of forma-
tion, growth characteristics, weight, and volume of tumors were observed. The histopathologic 
examination of tumors and organs were detected. For resistant tumors, the protein levels of 
Bcl-2, and BAX were detected by Western blot. Bcl-2, BAX, and caspase-3 genes were also 
detected. For K562/A02 cells xenograft tumors, 5-BrTet and MNP-Fe3O4 combined with DNR 
signiﬁ  cantly suppressed growth of tumor. A histopathologic examination of tumors clearly 
showed necrosis of the tumors. Application of 5-BrTet and MNP-Fe3O4 inhibited the expression 
of Bcl-2 protein and upregulated the expression of BAX and caspase-3 proteins in K562/A02 
cells xenograft tumor. It is concluded that 5-BrTet and MNP-Fe3O4 combined with DNR had a 
signiﬁ  cant tumor-suppressing effect on a MDR leukemia cells xenograft model.
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Multidrug resistance (MDR) is a well-deﬁ  ned phenomenon of cross-resistance of 
mammalian cells to a number of anticancer agents following exposure to one such 
drug. It is a major obstacle to successful chemotherapy in leukemia.1 More than 90% of 
patients with malignant tumor die of MDR. A diverse range of agents involved in MDR 
include alkaloid compounds and bacterial and fungal antibiotics such as anthracyclines 
and etoposide. An accepted mechanism of MDR is a reduced cellular accumulation and 
an altered subcellular distribution of cytotoxic drugs. In many instances, this is mediated 
by increased expression at the cell surface of the MDR1 gene product, P-glycoprotein 
(P-gp), a 170-kD energy-dependent efﬂ  ux pump. Different chemotherapeutic agents 
have been shown to induce the death of susceptible cells by apoptosis, and this can be 
inhibited by proteins such as Bcl-247 and Bcl-xL. The purpose of this paper is to ﬁ  nd 
a low mammalian toxicity, high-efﬁ  ciency, high-selectivity modulator.
Close attention has been paid to current nanoparticle techniques. The magnetic 
nanoparticle of Fe3O4 (MNP-Fe3O4)2,3 that we invented has good biocompatibility 
and no cytotoxicity. MNP-Fe3O4 can increase the intracellular effective concentration 
of chemotherapeutic drugs in vitro in order to reverse MDR.4,5 5-Bromotetrandrine International Journal of Nanomedicine 2009:4 74
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(5-BrTet), when highlighted by isoquinoline alkaloid, is a 
hypotoxic calcium channel blocker.6 5-BrTet inhibits the 
function of P-gp in order to accumulate anticancer drugs in the 
body.7 Most research on the reversal of MDR was on the basis 
of experiments in vitro.
This paper was to establish the xenograft leukemia model 
with stable MDR in nude mice; to investigate the reversal 
effect of 5-BrTet and MNP-Fe3O4 combined with dauno-
rubicin (DNR) in vivo and to search for possible reversal 
mechanisms in order to provide theoretic evidence for the 
clinical applications.
Material and method
Cell lines and cell culture
K562 cell was a cell line cloned from human chronic 
myelogenous leukemia by repeated passage in nude mice and 
in culture alternatively. The MDR leukemia cell K562/A02 
was established by stepwise selection with an increasing con-
centration of adriamycin (ADM). K562 cells were maintained 
in RPMI 1640 medium with 10% newborn bovine serum at 
37 °C in a humidiﬁ  ed 5% CO2 atmosphere. K562/A02 was 
cultured in a medium containing 1 μg/ml ADM for maintain-
ing MDR phenotype.
Experimental agents
Adriamycin (Hisun Phamaceutical Co., Zhejiang, China) 
and DNR (Main Luck Pharmaceuticals Inc., Shenzheng, 
China) 2 mg/ml stock solution were prepared with 0.01 mol/l 
phosphate buffer saline (PBS) (pH 7.4). Nutritional medium: 
RPMI1640 (Gibco Chemical Co., Carlsbad, CA, USA), calf 
serum (Gibco Chemical Co); MNP-Fe3O4 was provided by the 
Biological Science College at Southeast University, Nanjing; 
DNR conjugated with MNP-Fe3O4 colloidal suspension were 
prepared by mechanical absorption polymerization at 4 °C for 
48 h as reported previously. 5-BrTet (Kanghong Chemical Co, 
Chengdou, China) was diluted with 0.01 mol/l PBS (pH 7.4).
Experimental animals
Female BALB/c nude mice which were age-matched (four 
weeks of age) and weight-matched (16–22 g) were purchased 
from Shanghai National Center for Laboratory Animals. They 
were maintained in speciﬁ  c pathogen-free (SPF) facilities and 
fed with irradiated food. Indoor temperature was maintained 
at 22 °C and humidity was controlled at 45 ± 5%.
Xenograft leukemia model in nude mice
The two subclones of K562/A02 and K562 cells were 
inoculated subcutaneously into the back of athymic nude 
mice (1 × 107 cells/0.2 ml/each) respectively to establish 
the human leukemia xenograft models: the drug-resistant 
xenograft nude-mice models and the sensitive tumor-bearing 
xenograft nude-mice models.
Using animal ultrasonic equipment 
to evaluate tumor formation
Six days after cell inoculation, pink neoplasm had emerged 
in the inoculated part. We used animal ultrasonic equipment 
to detect the neoplasm.
Tumor-bearing nude mice divided into 
groups.   The effect of reversal of MDR 
in tumor-bearing nude mice determined
When the tumor size reached to 75–150 mm3, the drug-resistant 
and sensitive tumor-bearing nude mice were both assigned 
randomly to ﬁ  ve groups. Each group contained eight nude 
mice. The drugs were administered by intraperitoneal injec-
tion except for MNP-Fe3O4 copolymerizating DNR delivered 
by vena caudalis injection. In group A, the control group was 
treated with normal saline (NS) 0.2 ml/each day; in group B, 
DNR 1 mg/(kg⋅day); in group C, 5-BrTet 2.5 mg/(kg⋅day) 
combined with DNR 1 mg/(kg⋅day), 5-BrTet was administered 
one hour before DNR; in group D, NP-Fe3O4 combined with 
DNR 0.63 mg/(kg⋅day); in group E, 5-BrTet 2.5 mg/(kg⋅day) 
and MNP-Fe3O4 combined with DNR 0.63 mg/(kg⋅day), 
5-BrTet was administered one hour before MNP-Fe3O4. 
Each group was treated every day for 10 days. The incidence 
of formation, growth characteristics, weight, and volume of 
tumor were observed for each group, respectively. All the 
tumor-bearing nude mice were killed on the eleventh day to 
detect tumors and gains.
Tumor volume
Tumor dimensions were measured with digital calipers or 
animal ultrasonic inspection to obtain two diameters of 
the tumor formed. Tumor size was calculated by using the 
formula as follows: Tumor volume = l/2 × a × b2, where a is 
the longest diameter and b is the shortest. The inhibition rate 
(IR) (%) = (one-experimental group relative tumor volume 
[RTV]/control group RTV)⋅100%. RTV = Vx/V1, Vx and V1 
represent tumor volume on the X day and the ﬁ  rst day after 
treatment. Tumor weight was calculated by torsion balance 
and growth-inhibiting rat.
Histopathologic examination of tumors and organs
After the nude mice are killed, the tumors and organs must 
be ﬁ  xed in formalin immediately, hematoxylin and eosin 
stained, and observed by 400x light microscope.International Journal of Nanomedicine 2009:4 75
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Apoptosis-related proteins detected by Western blot 
for resistant tumors
Cellular nucleic protein was obtained by grinding the 
tumors as discussed previously. Protein concentration 
(Bcl-2, BAX, Caspase-3) was settled to 2 μg/μl. Each 
lane contained 40 μg proteins. The proteins were resolved 
by 10% SDS/PAGE for one hour, and then transferred to 
nitrocellulose membrane. After being blocked in Tris-
buffered saline/Tween-20 (TBST) with 5% skim milk 
overnight, the membrane was incubated with primary 
polyclonal antibody (1:500; Biolegend, San Diego, CA, 
USA) for one hour, and subsequently incubated with 
horseradish peroxidase-linked goat anti-rabbit secondary 
antibody (1:7500; Pierce, Rockford, IL, USA) for one 
hour. The protein bands were visualized by enhanced 
chemiluminescence regents (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA).
Quantitative real-time PCR analysis
After killing the nude mice, total RNA of tumor was 
isolated using TRIzol® Reagent (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA) according to the manu-
facturer’s protocol. One microgram of total RNA was 
used to generate cDNA using SuperScript™ II reverse 
transcriptase (Invitrogen Life Technologies). PCR primers 
were designed to amplify products within target and control 
sequences (Bcl-2, forward: 5'-GGGAGAACAGGGTAC-
GATAA-3'; reverse: 5'-CCACCGAACTCAAAGAAGG-3'. 
BAX, forward: 5'-TTTTGCTTCAGGGTTTCATC-3'; 
reverse: 5'-GACACTCGCTCAGCTTCTTG -3'. Caspase-3, 
forward: 5'-GCTATTGTGAGGCGGTTGT-3'; reverse: 
5'-TGTTTCCCTGAGGTTTGC-3'. GAPDH, forward: 
5'-CGGATTTGGTCGTATTG-3’; reverse: 5'-GAA-
GATGGTGATGGGATT-3'). Quantitative real-time PCR 
(QPCR) was performed by real-time monitoring of the 
increase in ﬂ  uorescence of SYBR Green I dye (Takara, 
Shiga, Japan) with Rotor-Gene 3000 (Corbett Research, 
Sydney, Australia).Each experiment was done in triplicate. 
The relative gene copy number was calculated by the 
concentration-CT standard curve method and normalized 
using the average expression of GAPDH.
Statistical analysis
The data was analyzed with SPSS v. 11.5 (SPSS Inc., 
Chicago, IL, USA) software. The signiﬁ  cance test used factor 
variance analysis and the difference had statistical signiﬁ  -
cance, p  0.05.
Results
The animal model of hematologic disease 
was established successfully
The median latency of K562 cells was six days when it formed 
neoplasm, which was shorter than that of K562/A02 cells at 
eight days. We used animal ultrasonic inspection to conﬁ  rm 
the presence of tumor. Figure 1 displays the tumor formation 
incidences of K562 and K562/A02 cells at 100%.
The relative tumor volume and inhibition 
rate of ﬁ  ve experimental groups for K562 
sensitive cells xenograft tumor
Six days after K562 cell inoculation, the tumors reached a 
volume of more than 100 mm3. The mice were divided into 
ﬁ  ve groups and subject to 10 days of treatment. When the 
K562 cell tumor-bearing nude mice were killed, the relative 
tumor volumes of the ﬁ  ve experimental groups were as follows: 
the control group A was 15.24 ± 0.10; groups B, C, D, and E 
were 5.79 ± 0.15, 5.77 ± 0.15, 5.78 ± 0.08, and 5.66 ± 0.06, 
respectively (p = 0.743). The inhibition rates of groups B, C, D, 
and E compared with the control group were 62.01 ± 0.31%, 
62.12 ± 0.11%, 62.11 ± 0.22%, and 62.82 ± 0.18%, respec-
tively (p = 0.678). The tumor weight was measured and the 
inhibition rate of tumor growth groups B, C, D, and E was 
calculated at 59.05 ± 0.14%, 59.64 ± 0.31%, 59.52 ± 0.37%, 
and 60.52 ± 0.44%, respectively (p = 0.748).
The relative tumor volume and inhibition 
rate of ﬁ  ve experimental groups for 
K562/A02 resistant cells xenograft tumor
Eight days after K562/A02 cells inoculation, the tumors 
reached a volume of more than 100 mm3. The mice were 
Figure 1 Animal ultrasonic inspection of pink neoplasm: tumor formation.International Journal of Nanomedicine 2009:4 76
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divided into ﬁ  ve groups and subject to 10 days of treatment. 
When K562/A02 cell tumor-bearing nude mice were killed, the 
relative tumor volumes of the ﬁ  ve experimental groups were 
as follows: the control group A was 12.94 ± 0.14; groups B, 
C, D, E were 12.47 ± 0.30, 9.30 ± 0.21, 7.26 ± 0.34, and 
4.89 ± 0.24, respectively (p = 0.024; Figure 2). The inhibition 
rates of groups B, C, D, and E compared with the control 
group were 3.68 ± 0.17%, 28.24 ± 0.32%, 40.80 ± 0.16%, 
62.76 ± 0.42%, respectively. There were signiﬁ  cant differ-
ences in groups B, C, D, and E (p = 0.015). The tumor weight 
was measured and the inhibition rates of tumor growth of 
groups B, C, D, and E were calculated at 1.34 ± 0.43%, 
28.08 ± 0.41%, 46.40 ± 0.22%, 59.75 ± 0.16%, respectively 
(p = 0.021).
Histopathologic examination of K562/
A02 resistant tumors and organs
In K562/A02-resistant tumors, the pathology of tumors 
from control group A and the DNR-alone group B showed 
more heterogeneity of neoplastic cells, karyomegaly, more 
mitotic ﬁ  gures, and vasiformation. Tumors from groups C 
and D showed a few necroses. The pathology of tumors 
from control group E showed obvious necrosis. There were 
no apparent histopathologic damage to organs such as the 
heart, liver, kidney, etc.
Western blot analysis of apoptosis-related protein 
expression in K562/A02 resistant tumors was performed. 
Application of 5-BrTet and MNP-Fe3O4 downregulated 
the expression of Bcl-2 protein compared with the control 
group and upregulated the expression of BAX and caspase-3 
protein (Figure 3).
Expressions of Bcl-2, BAX, and caspase-3 
genes in K562/A02-resistant tumors 
and K562 tumors
The expression levels of Bcl-2, BAX, and caspase-3 genes 
were detected by PCR. Compared with the control group, 
both BAX and caspase-3 mRNA expression increased mark-
edly in in K562 tumors in group E. The expression of Bcl-2 
was signiﬁ  cantly suppressed by application of 5-BrTet and 
MNP-Fe3O4 (Table 1).
Discussion
Chemotherapy is the main method of leukemia therapy. 
The clinical therapeutic effect is not as good as imagined, 
although more and more new chemotherapeutic drugs are 
emerging. One of the most important reasons for this clinical 
effect is MDR. The common cause of MDR is believed to 
be the enhanced expression of a transmembrane glycopro-
tein termed P-glycoprotein (P-gp) coded by the mdr1 gene 
in cancer cells.8,9 Some of the drug molecules that diffuse 
into cells are removed by P-gp. The industry develop-
ment of MDR modulators is extremely fast, but their weak 
activity and toxic reaction limit clinical and therapeutic 
applications. Recently, exploratory research in nanoparticle 
medicine showed a reversal in MDR by the application of 
Control group
HE stain magnification of 400
DNR 
HE stain magnification of 400
DNR + BrTet
HE stain magnification of 400
DNR  MNP-Fe3O4
HE stain  magnification of 400
) + BrTet
HE stain  magnification of 400
(DNR  MNP-Fe3O4
Figure 2 Histopathologic examination of K562/A02 resistant tumors of different groups (hematoxylin and eosin stain, 400 × light microscope).
Abbreviations: BrTet, 5-bromotetrandrine; DNR, daunorubicin; HE, hematoxylin and eosin; MNP-Fe3O4, magnetic nanoparticle of Fe3O4.International Journal of Nanomedicine 2009:4 77
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magnetic nanoparticles loaded with chemotherapeutics.10–12 
MNP-Fe3O4 has been considered as a potential MDR cancer 
reversal agent, although its involved molecular mechanism 
has not been well elucidated. The diameter of MNP-Fe3O4 
manufactured by the Biological Science College at Southeast 
University was 20–30 nm, which suits reversal of MDR.13 
Some research reports that the fraction of nanoparticle-loaded 
doxorubicin (Dox), which enters cells by endocytosis, may 
be associated with solid lipids and is not easily cleared from 
the cell by P-gp drug efﬂ  ux. Nanoparticle-loaded Dox may 
inhibit P-gp function. 5-BrTet could step down the toxicity of 
chemotherapeutics and may not impact the pharmacokinetics 
of chemotherapeutics in vivo.14
This experiment shows that the leukemia xenograft 
nude-mice model maintains MDR. 5-BrTet and MNP-Fe3O4 
combined with DNR had a signiﬁ  cant tumor-suppressing 
effect on the MDR leukemia cells xenograft model. This 
activity may enhance apoptosis. We propose further studies 
to determine whether 5-BrTet and MNP-Fe3O4 may suppress 
tumor cell proliferation and induce apoptosis by blocking 
multiple pathways. Our results indicated that application of 
5-BrTet and MNP-Fe3O4 had a better effect in reversal MDR 
than DNR, 5-BrTet combined with DNR, or MNP-Fe3O4 
combined with DNR. 5-BrTet and MNP-Fe3O4 may be the 
most promising MDR modulators for eventual assessment in 
the clinic. 5-BrTet and MNP-Fe3O4 combined with DNR had 
a signiﬁ  cant tumor-suppressing effect on the MDR leukemia 
cells xenograft model.
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Figure 3 Western blot of apoptosis-related protein expression in K562/A02-resistant tumors.
Abbreviations: BrTet, 5-bromotetrandrine; DNR, daunorubicin; MNP-Fe3O4, magnetic nanoparticle of Fe3O4.
Table 1 Expressions of Bcl-2, BAX, and caspase-3 genes in different groups ( x   ¯ ± SD)
Gene 
expressions
k562/A02 
control group
k562/A02 
DNR 1 mg/kg
k562/A02 DNR 
MNP-Fe3O4 
0.63 mg/kg
k562/A02 DNR 
1 mg/kg + 2-BrTet 
5 mg/kg
k562/A02 (DNR 
MNP-Fe3O4) 
0.63 mg/kg + 5-BrTet 
2.5 mg/kg
k562 control 
group
Bcl-2 9.364 ± 0.010 6.248 ± 0.120 4.012 ± 0.200 3.679 ± 0.138 2.004 ± 0.025 8.567 ± 0.225
BAX 2.013 ± 0.085 1.968 ± 0.038 6.025 ± 0.106 5.994 ± 0.173 11.256 ± 0.166 5.689 ± 0.281
Caspase-3 2.063 ± 0.047 1.958 ± 0.057 3.668 ± 0.205 4.025 ± 0.193 12.334 ± 0.187 3.665 ± 0.043
Abbreviations: BrTet, 5-bromotetrandrine; DNR, daunorubicin; MNP-Fe3O4, magnetic nanoparticle of Fe3O4.International Journal of Nanomedicine 2009:4 78
Chen et al
References
  1.  Sarkar FH, Li Y. Using chemopreventive agents to enhance the efﬁ  cacy 
of cancer therapy. Cancer Res. 2006;66:3347–3350.
 2. Cheng FY, Su CH, Yang YS, et al. Characterization of aqueous dis-
persions of Fe3O4 nanoparticles and their biomedical applications. 
Biomaterials. 2005;26(7):729–738.
 3. Zhang R, Wang X, Wu C, et al. Synergistic enhancement effect of 
magnetic nanoparticles on anticancer drug accumulation in cancer cells. 
Nanotechnology. 2006;17:3622–3626.
 4. Song M, Zhang R, Dai Y, et al. The in vitro inhibition of multidrug 
resistance by combined nanoparticulate titanium dioxide and UV 
irradition. Biomaterials. 2006;27(23):4230–4238.
  5.  Wang X, Zhang R, Wu C, et al. The application of Fe(3)O(4) nanopar-
ticles in cancer research: A new strategy to inhibit drug resistance. 
J Biomed Mater Res A. 2007;80(4):852–860.
  6.  Fu L, Liang Y, Deng L, et al. Characterization of tetrandrine, a potent 
inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer 
Chemother Pharmacol. 2004;53:349–356.
  7.  Li J, Xu L Z, He K L, et al. Reversal effects of nomegestrol acetate on 
multidrug resistance in adriamycin-resistant MCF7 breast cancer cell 
line. Breast Cancer Res. 2001;3:253–263.
 8.  Schdert T, Kurbocher RCM, Benzm, et al. Induction of MDR1 gene 
expression by antieoplatic agents in ovarin cancer cell lines. Anticancer 
Res. 2002;22:2199–2202.
  9.  Michale M, Gottesman G. Mechanisms of cancer drug resistance. Annu 
Rev Med. 2002;53:615–627.
10. Wong HL, Rauth AM, Bendayan R, et al. A new polymer-lipid 
hybrid nanoparticle system increases cytotoxicity of doxorubicin 
against multidrug-resistant human breast cancer cells. Pharm Res. 
2006;23:1574–1585.
11.  Alexiou C, Jurgons R, Schmid R, et al. [Magnetic drug targeting – a 
new approach in locoregional tumor therapy with chemotherapeutic 
agents. Experimental animal studies.] HNO. 2005;53(7):618–622.
12.  Omid CF, Cheng J, Benjamin AT, et al. Targeted nanoparticle-aptamer 
bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci 
U S A. 2006;103(16):6315–6320.
13.  Thomas K, Sayre P. Research strategies for safety evaluation of nano-
materials, Part I: Evaluating the human health implications of exposure 
to nanoscale materials. Toxicol Sci. 2005;87:316–321.
14. Wang  FP,  Wang  L, Yang JS, et al. Reversal of P-glycoprotein-dependent 
resistance to vinblastine by newly synthesized bisbenzylisoquinoline 
alkaloids in mouse leukemia P388 cells. J Biol Pharm Bull. 2005;28:
1979–1982.